Setmelanotide is under consideration for other rare genetic disorders associated with obesity including Bardet–Biedl syndrome, Alstrom syndrome, POMC, and other MC4R pathway heterozygous deficiency obesities. This evidence concerns the gene MC4R and hereditary disease.